AU8167498A - Method for inducing a systemic immune response to a hepatitis or hiv antigen - Google Patents

Method for inducing a systemic immune response to a hepatitis or hiv antigen

Info

Publication number
AU8167498A
AU8167498A AU81674/98A AU8167498A AU8167498A AU 8167498 A AU8167498 A AU 8167498A AU 81674/98 A AU81674/98 A AU 81674/98A AU 8167498 A AU8167498 A AU 8167498A AU 8167498 A AU8167498 A AU 8167498A
Authority
AU
Australia
Prior art keywords
hepatitis
inducing
immune response
hiv antigen
systemic immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81674/98A
Inventor
Darryl M. See
Jackie R. See
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOSPHERE TECHNOLOGIES Inc
Original Assignee
Bio Sphere Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/948,568 external-priority patent/US6207185B1/en
Priority claimed from US09/007,297 external-priority patent/US6117449A/en
Application filed by Bio Sphere Technology Inc filed Critical Bio Sphere Technology Inc
Publication of AU8167498A publication Critical patent/AU8167498A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
AU81674/98A 1997-06-26 1998-06-25 Method for inducing a systemic immune response to a hepatitis or hiv antigen Abandoned AU8167498A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US88296897A 1997-06-26 1997-06-26
US08882968 1997-06-26
US08/948,568 US6207185B1 (en) 1996-03-22 1997-10-10 Method for inducing a systemic immune response to an HIV antigen
US08948568 1997-10-10
US09007297 1998-01-14
US09/007,297 US6117449A (en) 1996-03-22 1998-01-14 Method for inducing a systemic immune response to a hepatitis antigen
PCT/US1998/013194 WO1999000142A1 (en) 1997-06-26 1998-06-25 Method for inducing a systemic immune response to a hepatitis or hiv antigen

Publications (1)

Publication Number Publication Date
AU8167498A true AU8167498A (en) 1999-01-19

Family

ID=27358330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81674/98A Abandoned AU8167498A (en) 1997-06-26 1998-06-25 Method for inducing a systemic immune response to a hepatitis or hiv antigen

Country Status (2)

Country Link
AU (1) AU8167498A (en)
WO (1) WO1999000142A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850872A1 (en) * 2003-02-12 2004-08-13 Ethypharm Sa Composition containing an antigen of human immune deficiency virus, for use as a vaccine, comprises multilamellar vesicles with an internal liquid crystal structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes

Also Published As

Publication number Publication date
WO1999000142A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
AU4878096A (en) Hepatitis b vaccine
NO976060D0 (en) Vaccines against hepatitis C
AU5504996A (en) Composition for inducing a mucosal immune response
AU9052091A (en) Vaccines based on hepatitis b surface antigen
AU709406C (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
AU4827299A (en) Systemic immune activation method using nucleic acid-lipid complexes
AU3210997A (en) Dna vaccines for eliciting a mucosal immune response
AU6449996A (en) Improved antibodies to Plasmodium falciparum
AU634518B2 (en) Hepatitis B core antigen conjugates
AU7983198A (en) Improved methods for inducing an immune response
IL116100A0 (en) Fork lift
HU9500417D0 (en) Hepatitis a vaccine
AU5679394A (en) Hepatitis b virus vaccines
AU8167498A (en) Method for inducing a systemic immune response to a hepatitis or hiv antigen
AU8016998A (en) Method for detecting hiv antibodies and antigens used to this end
GB2279076B (en) Antibodies to fungal antigens
AU682805B1 (en) Method for inducing a systemic immune response to an antigen
AU7585998A (en) Controlling immune response to specific antigens
AU2517895A (en) Hiv polyprotein immunogens
GB9522485D0 (en) Hepatitis b surface antigen variants
AU6295896A (en) Assay for hepatitis a virus-specific antibodies
AU4335089A (en) A malaria antigen
AU7835898A (en) A method of enhancing antigen-specific peripheral immune tolerance
GB9514118D0 (en) Novel attenvated HIV vaccine
HU0400424D0 (en) Hepatitis virus vaccines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase